Global TCR Therapy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increased need of TCR therapies for cancer patients and effectiveness of TCR therapies against cancer are the major factors driving the growth of Global TCR Therapy Market.
T-cell receptors (TCRs) are proteins that recognize small protein fragments (peptides) on the surface of antigen-presenting cells. Each T cell has its own TCR, which is generated by randomly assorting genes. In 2017, approvals for genetically engineered T cell therapies were granted. TCR Therapies include taking T cells from patients and equipping them with a new T cell receptor that allows them to target particular cancer antigens in addition to stimulating and extending the available anti-tumor T cells. The treatment can be more tailored to individuals by allowing doctors to select an optimum goal for each patient's tumor and distinct types of T cells to engineer. This, in turn, could give patients more hope for relief. Activated T cells are given unique receptors that target their complementary cancer antigens in engineered TCR therapy. This dramatically improves treatment personalization and increases the likelihood of positive health outcomes. TCR therapy is a more flexible treatment option that can be used to treat a wider range of cancers. The advancement of techniques to reduce the time it takes to separate T cells and the creation of low-cost separation equipment might actually open more market growth opportunities.
People were forced to stay indoors during the Covid-19 pandemic, and as a result of the lockout, medical treatments and facilities, as well as diagnostic methods and cancer surgeries, were delayed thus, it has shown a decline impact on the market growth of TCR therapy. Despite of that, the ability of TCR-T cell immunotherapy for COVID-19 regulation is being investigated by researchers at Duke-NUS Medical School in Singapore. The TCR therapy in Covid-19 treatment success may increase chances of growth in market of TCR therapies.
Global TCR Therapy Market report is segmented on the basis of type, application, end-user and region & country level. Based upon type, Global TCR Therapy Market is classified into transduction of chimeric antigen receptors and transduction of TCR α/β heterodimer. Based on application, the market is divided into refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer and other. Based upon end-user, the market is divided into hospitals, clinics & ambulatory centers, cancer research institutes and others.
The regions covered in Global TCR Therapy Market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global TCR therapies is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some key players for Global TCR Therapy Market are Adaptimmune Therapeutics PLC, Immunocore, Medigene, Adaptive Biotechnologies, Lion TCR, TCR2 Therapeutics, Inc., RootPath, Kite Pharma, Guangzhou Xiangxue Pharmaceutical Co., Ltd, Eureka Therapeutics and others.
News: T-TCR cure's Therapy will be developed by Immunotech in China.
January 20th, 2020; T-Cure Bioscience has entered into a license agreement with Immunotech Biopharm in China for the research and production of T-800TCR Cure's candidate, a HERV-E-targeting T-cell receptor (TCR) therapeutic for renal cell cancer. Via a structured joint research and development arrangement, T-Cure is currently developing 800TCR in the United States in partnership with the National Heart, Lung, and Blood Institute (NHLBI). The candidate is being tested in a phase I test at NHLBI for the treatment of metastatic clear cell renal cell carcinoma that has failed to respond to angiogenic and checkpoint inhibitors. HERV-E targets, according to T-Cure, are a new frontier of TCR targets with significant clinical potential for cancer immunotherapy. Immunotech will pay T-Cure an upfront payment, as well as future development milestone payments and tiered royalties based on net sales of the drug. In China, Immunotech will have the exclusive rights to grow and market 800TCR.
The major factor driving the growth of Global TCR Therapy Market is increasing need of TCR Therapies for cancer patients. TCR-T-cell therapy has advanced quickly and has emerged as a promising treatment option for a variety of cancers, especially solid tumors. Cancers of the lung, breast, prostate, colon, and rectum, as well as bladder cancers, are classified as solid tumors. According to Journal of Technology in Cancer Research and Treatment, TCRs work by interacting with peptide-major histocompatibility complexes (pMHC), which are complexes formed by peptide bound to MHC. pMHCs are formed when intracellular antigens are broken up into peptide chains and displayed by MHC molecules. Proteolysis cleaves cytoplasmic proteins to be expressed by class I MHC proteins into peptide chains, the majority of which are defective ribosomal translation products. These peptides are then bound to class I MHC proteins, which are found on the cell surface of all nucleated cells. Antigen-presenting cells (APCs) are cells that express class II MHC proteins. They use endocytosis to internalize foreign material proteins and cleave them into peptide chains that can bind to class II MHC proteins. T-cell receptors, which must be matched to patients' human leukocyte antigen (HLA) alleles, identify these pMHCs and cause cancer cell death. Thus, the increasing number of cancer patient’s demands need of TCR Therapies. For instance, according to WHO, in 2018, 18.1 million people worldwide were diagnosed with cancer, with 9.6 million deaths from it. Lung cancer is the most commonly diagnosed cancer (11.6% of all cases), followed by female breast cancer (11.6%) and colorectal cancers (10.2%). Lung cancer is the most common cause of cancer death (18.4% of all deaths), followed by colorectal (9.2%) and stomach cancers (8.2%).
In addition, effectiveness of TCR therapies against cancer is also fostering the market growth. TCR-T has a wide range of applications that could make it a highly effective immunotherapy for cancer patients, including improved efficacy, increased TCR affinity, increased TCR expressions, and increased protection. For instance, according to Journal of Annals of Blood, TCR-T clinic trials revealed that improved affinity TCR-T provided 80% clinical responses in advanced myeloma patients. Patients in the clinical trial received five days of chemotherapy and two days of RT to prepare their immune systems for receiving MART-1 and gp100 unique TCR-T cells. Combining chemotherapy/radiation with TCR-T resulted in the creation of more effective cancer ACT therapies.
However, high cost of equipments used for TCR therapies and extra time consumed for separation of T cells for TCR therapies may hamper the market growth. In spite of that, increased efficiency and assuring more safety to the patients can offer more opportunities for the further growth of the global TCR technologies market.
The Global TCR Therapy Market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the Global TCR Therapy Market within the forecast period owing to the increasing number of cancer cases and growing demand of TCR therapies for treating the solid tumors rather than CAR-T methods in this region. For instance, according to American Cancer Society Inc., at least 42% newly diagnosed cancers in the United States. The rate was at about 750,000 cases in 2020. Cancer is the leading cause of death in the working-age population in the United States (ages 20-65 years). According to Journal of Technology in Cancer Research & Treatment, in the United States in 2018, melanoma accounted for nearly 92 percent of new cases of skin cancer and 69 percent of skin cancer-related deaths. The second category includes leukemia and gastrointestinal cancers, which is the subject of 24 studies. Just 34 (approximately 16%) of the 210 cancers mentioned in 84 clinical trials are hematological malignancies, and 84 percent of the cancer types targeted by these 84 clinical trials are solid tumors. Maybe since CAR-T has already shown its efficacy in treating hematological malignancies, while its effects on solid tumors have been shown to be ineffective in comparison to TCR-T-cell therapy in numerous studies.
Asia Pacific is expected to witness a significant growth in the global TCR therapy market owing to the growing prevalence of cancer infected people in this region. For instance; according to Chinese Journal of Cancer Research, in 2017 cancer caused about 62.9 million disability-adjusted life years (DALYs) in China. The most significant contribution was made by solid tumor cancers such as lung cancer, which was followed by liver cancer, stomach cancer, and esophageal cancer.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||XX|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||XX|
|Tables, Charts & Figures:||175|
|Key Players/Companies||Adaptimmune Therapeutics PLC, Immunocore, Medigene, Adaptive Biotechnologies, Lion TCR, TCR2 Therapeutics, Inc., RootPath, Kite Pharma, Guangzhou Xiangxue Pharmaceutical Co., Ltd, Eureka Therapeutics and others|
|Segments Covered||By Type, By Application, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa